Condition
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Total Trials
5
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (2)
Trial Status
Completed3
Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06817343Phase 1Active Not Recruiting
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT04270747Phase 3CompletedPrimary
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
NCT02243878Phase 3CompletedPrimary
Stereotactic Radiotherapy for Wet AMD (STAR)
NCT02253030RecruitingPrimary
OCT Angiography in Wet AMD
NCT02061865Phase 1CompletedPrimary
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Showing all 5 trials